



10 - 9 - 1

1645

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED
OCT 11 2001
TECH CENTER 1600/2900
#5

In Re the Application of:

LAHN et al.

Serial No.: 09/826,319

Filed: April 3, 2001

Atty. File No.: 2879-80

For: "METHOD TO INHIBIT AIRWAY
HYPERRESPONSIVENESS USING
AEROSOLIZED T CELL
RECEPTOR ANTIBODIES"

) Group Art Unit:

)

) Examiner:

)

)

)

)

)

)

)

)

)

)

)

)

INFORMATION DISCLOSURE
STATEMENT

EXPRESS MAIL: EL822579889

Commissioner of Patents
Washington, D.C. 20231

Dear Sir:

Pursuant to Applicants' duty of disclosure under 37 CFR § 1.56 and 37 CFR §§ 1.97-1.98, Applicants hereby provide a copy of each of the documents identified on the enclosed PTO Form 1449, although Applicants do not admit that any of such documents, alone or in any combination, are considered to be material to patentability as defined in 37 CFR § 1.56(b). Moreover, the inclusion of these documents is not to be construed as an admission by Applicants that each such document is prior art as to the above-identified patent application.

Respectfully submitted,

SHERIDAN ROSS P.C.

By: Angela Dallas
Angela K. Dallas
Registration No. 42,460
1560 Broadway, Suite 1200
Denver, CO 80202-5141
(303) 863-9700

Date: October 4, 2001

FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.
2879-80SERIAL NO.
09/826,319INFORMATION DISCLOSURE STATEMENT
(Use several sheets if necessary)APPLICANT
LAHN et al.FILING DATE
April 3, 2001

GROUP ART

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROP.
	1	5,185,250	2/9/93	Brenner et al.	435	69.3	
	2	5,223,426	6/29/93	Skibbens et al.	435	240.27	
	3	6,054,292	4/25/00	Hillman et al.	435	69.1	
	4	6,113,901	9/5/00	Bluestone	424	154.1	
	5	6,165,463	12/26/00	Platz et al.	424	130.1	
	6	6,171,799	1/9/01	Skibbens et al.	435	7.1	

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB CLASS	TRANSLATION	
							YES	NO
	7	WO 01/22816	05.04.2001	PCT				

OTHER ART (Including Author, Title, Date, Pertinent Pages, etc.)

8	Fahy et al., <i>Am. J. Respir. Crit. Care Med.</i> , 160 (3):1023-1027 (1999)
9	Hamelmann et al., <i>J. Exp. Med.</i> , 183 :1719-1729 (1996)
10	Holt, <i>J. Exp. Med.</i> , 183 :1297-1301 (1996)
11	Huber et al., <i>J. Immunol.</i> , 165 :4174-4181 (2000)
12	Kon et al., <i>Lancet</i> , 352 :1109-13 (1998)
13	Kon et al., <i>Inflamm. Res.</i> , 48 :516-523 (1999)
14	Lahn et al., <i>Nature Medicine</i> , 5 (10):1150-1156 (1999)
15	Milgrom et al., <i>N. Engl. J. Med.</i> , 341 :1966-1973 (1999)
16	Offner et al., <i>Springer Semin Immunopathol</i> , 21 :77-90 (1999)
17	Seymour et al., <i>J. Exp. Med.</i> , 187 (5):721-731 (1998)
18	Takeda et al., <i>J. Exp. Med.</i> , 186 (3):449-454 (1997)
19	Yocum, <i>Semin Arthritis Rheum</i> , 29 :27-35 (1999)

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.